ZED1227

ZED1227 is a first-in-class, orally administered small molecule inhibitor of tissue transglutaminase 2 (TG2), developed primarily for the treatment of celiac disease. It selectively binds to the active state of TG2, forming a stable covalent bond with its catalytic cysteine residue. By inhibiting TG2, ZED1227 blocks the deamidation and crosslinking of gliadin peptides in the small intestine—a key step in triggering immune responses that cause mucosal damage and inflammation in celiac disease. Clinical studies have shown that ZED1227 can prevent gluten-induced intestinal injury and inflammation when used alongside a gluten-free diet. The drug is also under investigation for nonalcoholic steatohepatitis (NASH). The developer is Zedira GmbH[1][3][5][6].

Other names

TAK-227TAK227TAK 227ZED 1227ZED1227ZED-1227